Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (GB:0A3M)
LSE:0A3M
BioNTech SE (0A3M) Share Price & Analysis
3 Followers
0A3M Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$85.38 - $125.74
Previous Close$87.18
Volume4.30K
Average Volume (3M)4.13K
Market Cap
$20.73B
Enterprise Value$4.40B
Total Cash (Recent Filing)€16.55B
Total Debt (Recent Filing)€219.10M
Price to Earnings (P/E)21.0
Beta0.67
Next Earnings
May 06, 2024EPS Estimate
-$0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.16
Shares Outstanding237,725,735
10 Day Avg. Volume1,751
30 Day Avg. Volume4,125
Standard Deviation0.29
R-Squared0.00717
Alpha0.14
Financial Highlights & Ratios
Price to Book (P/B)1.09
Price to Sales (P/S)7.09
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$111.64Price Target Upside28.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
BioNTech SE News
PremiumCompany Announcements
BioNTech SE Virtual AGM Scheduled for May 2024
PremiumCompany Announcements
BioNTech Reports Promising Cancer Vaccine Data
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsAutogene cevumeran demonstrates long-term benefit at three-year follow-up in Phase 1 trial, showing sustained immune responses and significantly longer median recurrence-free survival in patients.
Financial PositionBioNTech ended the year with a strong cash position, enhancing its ability to make meaningful acquisitions and invest in its expansive pipeline, aiming to bring multiple platforms to the market.
Pipeline DevelopmentBioNTech is advancing its oncology pipeline with several promising treatments in clinical trials, and the anticipation of clinical updates at upcoming medical conferences could provide further insights into their potential.
Bears Say
COVID-19 Vaccine OutlookWith the transition of the pandemic into an endemic phase, significantly lower demand for COVID-19 boosters is expected to result in record low sales for Comirnaty in the coming years.
Financial PerformanceBioNTech's significant revenue miss and Pfizer COVID-19 vaccine inventory write-off signal ongoing difficulties in predicting vaccine demand and managing inventory.
Pipeline DevelopmentDespite BioNTech setting ambitious goals for its oncology pipeline, the market is skeptical, potentially leading to downward revisions in long-term estimates.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.68% Insiders
4.49% Mutual Funds
1.22% Other Institutional Investors
93.60% Public Companies and
Individual Investors
0A3M FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest share price was $85.38 and its highest was $125.74 in the past 12 months.
What is BioNTech SE’s market cap?
Currently, no data Available
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is May 06, 2024 which is in 8 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Mar 20, 2024. The company reported $2.034 earnings per share for the quarter, missing the consensus estimate of $2.543 by -$0.509.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE does not currently pay dividends.
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is -$0.98.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 237,725,740 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of $2.034 in its last earnings report, missing expectations of $2.543. Following the earnings report the stock price went down -4.613%.
Which hedge fund is a major shareholder of BioNTech SE?
Among the largest hedge funds holding BioNTech SE’s share is PRIMECAP Management Co. It holds BioNTech SE’s shares valued at 503M.
---
BioNTech SE Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$111.64 (28.06% Upside)
$111.64 (28.06% Upside)
Blogger Sentiment
Bullish
GB:0A3M Sentiment 86%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $9.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.14%
12-Months-Change
Fundamentals
Return on Equity
4.56%
Trailing 12-Months
Asset Growth
2.29%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
---
0A3M Company Deck
---
0A3M Earnings Call
Q4 2024
0:00 / 0:00
---
0A3M Stock 12 Months Forecast
Average Price Target
$111.64
▲(28.06% Upside)
Technical Analysis
Best Analysts Covering 0A3M
1 Year
1 Year Success Rate
7/23 ratings generated profit
1 Year Average Return
+21.13%
reiterated a buy rating 12 months ago
Copying Zhiqiang Shu's trades and holding each position for 1 Year would result in 30.43% of your transactions generating a profit, with an average return of +21.13% per trade.
---